Observational studyFrontiers in endocrinology2025
Association between endometrial cancer and subsequent risk of fracture: a national cohort study.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Most endometrial cancer (EC) cases are estrogen-dependent, and some are associated with diabetes mellitus (DM). We aimed to estimate the risk of fracture among patients with EC and those with DM. Materials and methods: A total of 20814 patients with EC were identified from the Taiwan National Cancer Registry from 2007 to 2018, with the outcome ascertainment using the National Health Insurance Research Database from 2004 to 2019. This observational study investigated the hazard ratios (HRs) for fracture and mortality events using Cox proportional hazards regression, with 95% confidence intervals (CIs). We adjusted baseline comorbidities, cancer therapy, cancer staging and grade, and pathological status of estrogen receptor and progesterone receptor. Considering the competing death events, we estimated the subdistribution hazard model to predict the probability of the fracture risk in the competing risks context. Results: Among 15,505 EC patients, there were 3,044 patients with and 12,461 patients without DM. Patients with EC exhibited a no significant association of fracture when compared to the matched general population. EC patients with DM, compared to those without DM, had a significantly increased odds of osteoporotic fracture (HR 1.29 [95% CI 1.08-1.55]), hip fracture (HR 2.37 [95% CI 1.44-3.92]), and vertebral fracture (HR 1.71 [95% CI 1.06-2.74]). Patients with DM had a no significant association of upper extremity fracture (HR 1.33 [95% CI 0.95-1.87]) compared with those with EC but without DM. Conclusions: EC patients had a no significant association of fracture, while DM increased the fracture risk in EC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.